Close

Aristotle (ARTL) Reports First Patient in CAReS Study with ART27.13 for Treatment of Cancer-Related Anorexia and Weight Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. IBM
8. V
9. KMB
10. WBS


Go back to Aristotle (ARTL) Reports First Patient in CAReS Study with ART27.13 for Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

April 12, 2021 8:30 AM EDT

Initial safety data expected from CAReS Study before end of 2021

Targeting multi-billion market with no approved therapies for cancer-related anorexia

LA JOLLA, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling signaling pathways, including the... More